Abstract: Provided are methods of producing exosomes by culturing isolated stem cells with an effective amount of at least one immunoregulatory factor. The thus-produced exosomes are enriched in anti-inflammatory miRNAs and/or miRNAs that inhibits the a epithelial-mesenchymal transition.

Abstract: A pharmaceutical composition for treating diseases related to inflammation or injury such as ARDS, comprising: (a) an active material derived from human somatic cells, the active ingredient being an extracellular vesicle produced by human somatic cells; and (b) a pharmaceutically acceptable carrier. The somatic cells are selected from human tissue, bone marrow and/or blood-derived stem cells, etc. The dosage form of the pharmaceutical composition is selected from an atomized inhalation agent, eye drops and nasal drops. The pharmaceutical composition has storage stability and high dispersibility superior to those of a living cell formulation. A method for preparing an extracellular vesicle, comprising steps of culturing human somatic cells, removing cells from a culture system, mixing a culture solution with polyethylene glycol to form an extracellular vesicle modified by PEG, centrifuging, resuspending, etc.

Abstract: A composition for treating articular cartilage defects, and a manufacturing method, and a kit thereof, the composition comprising: a therapeutically effective amount of fat-derived mesenchymal progenitor cells, serum albumin solution, and sodium hyaluronate, Above 95% of the fat-derived mesenchymal progenitor cells have the surface antigen CD90, CD73, CD29, and CD49d, and express cytokines selected from TGF-?1, HGF, and VEGF. The composition has the effect of treating articular cartilage defects.

Abstract: This invention features our discovery on usages of Methylenetetrahydrofolate Reductase (MTHFR) gene polymorphisms in predicting homocysteine (Hcy) level and/or incidence and prognosis of diseases associated with increased Hcy level in a subject, as well as predicting treatment effects of medicines in the category of Angiotension Converting Enzyme Inhibihor (ACEI) with and without combination with B Vitamins. This invention also features our discovery on laboratory and analytical methods that are essential to the above described usages of MTHFR gene polymorphisms. In addition, this invention features a kit that has translated the above discoveries into a practical and reliable tool that can be applied to accomplish the above described usages of MTHFR gene polymorphisms. This invention represents an important step in realizing personalized medicine, with the goal to tailor diagnosis, prevention and treatment strategy to meet individual needs.